These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1284 related articles for article (PubMed ID: 31028147)

  • 21. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
    Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
    Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
    [No Abstract]   [Full Text] [Related]  

  • 22. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
    Wei SC; Anang NAS; Sharma R; Andrews MC; Reuben A; Levine JH; Cogdill AP; Mancuso JJ; Wargo JA; Pe'er D; Allison JP
    Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22699-22709. PubMed ID: 31636208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma.
    Woods DM; Ramakrishnan R; Laino AS; Berglund A; Walton K; Betts BC; Weber JS
    Clin Cancer Res; 2018 Dec; 24(24):6236-6247. PubMed ID: 30131384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
    Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
    Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature.
    Grecea M; Marabelle A; Ammari S; Massard C; Champiat S
    Oncologist; 2020 May; 25(5):369-374. PubMed ID: 32091646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer.
    Zhang Y; Wang F; Sun HR; Huang YK; Gao JP; Huang H
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2209-2222. PubMed ID: 33891173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activated CTLA-4-independent immunosuppression of Treg cells disturbs CTLA-4 blockade-mediated antitumor immunity.
    Watanabe T; Ishino T; Ueda Y; Nagasaki J; Sadahira T; Dansako H; Araki M; Togashi Y
    Cancer Sci; 2023 May; 114(5):1859-1870. PubMed ID: 36762794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer.
    Sasaki A; Nakamura Y; Mishima S; Kawazoe A; Kuboki Y; Bando H; Kojima T; Doi T; Ohtsu A; Yoshino T; Kuwata T; Akimoto T; Shitara K
    Gastric Cancer; 2019 Jul; 22(4):793-802. PubMed ID: 30627987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody.
    Ohmura H; Yamaguchi K; Hanamura F; Ito M; Makiyama A; Uchino K; Shimokawa H; Tamura S; Esaki T; Mitsugi K; Shibata Y; Oda H; Tsuchihashi K; Ariyama H; Kusaba H; Oda Y; Akashi K; Baba E
    Br J Cancer; 2020 May; 122(10):1507-1517. PubMed ID: 32203221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
    Gide TN; Quek C; Menzies AM; Tasker AT; Shang P; Holst J; Madore J; Lim SY; Velickovic R; Wongchenko M; Yan Y; Lo S; Carlino MS; Guminski A; Saw RPM; Pang A; McGuire HM; Palendira U; Thompson JF; Rizos H; Silva IPD; Batten M; Scolyer RA; Long GV; Wilmott JS
    Cancer Cell; 2019 Feb; 35(2):238-255.e6. PubMed ID: 30753825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade.
    Rauch DA; Conlon KC; Janakiram M; Brammer JE; Harding JC; Ye BH; Zang X; Ren X; Olson S; Cheng X; Miljkovic MD; Sundaramoorthi H; Joseph A; Skidmore ZL; Griffith O; Griffith M; Waldmann TA; Ratner L
    Blood; 2019 Oct; 134(17):1406-1414. PubMed ID: 31467059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased tumor-infiltrating CD45RA
    Mao FY; Kong H; Zhao YL; Peng LS; Chen W; Zhang JY; Cheng P; Wang TT; Lv YP; Teng YS; Fu XL; Liu YG; Wu XL; Hao CJ; You N; Luo P; Yu PW; Zou QM; Guo G; Zhuang Y
    Cell Death Dis; 2017 Aug; 8(8):e3002. PubMed ID: 28817117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
    Selby MJ; Engelhardt JJ; Johnston RJ; Lu LS; Han M; Thudium K; Yao D; Quigley M; Valle J; Wang C; Chen B; Cardarelli PM; Blanset D; Korman AJ
    PLoS One; 2016; 11(9):e0161779. PubMed ID: 27610613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Brief Communication on Circulating PD-1-positive T-Regulatory Lymphocytes in Melanoma Patients Undergoing Adjuvant Immunotherapy With Nivolumab.
    Gambichler T; Schröter U; Höxtermann S; Susok L; Stockfleth E; Becker JC
    J Immunother; 2019 Sep; 42(7):265-268. PubMed ID: 31145230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
    Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
    Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.
    Champiat S; Dercle L; Ammari S; Massard C; Hollebecque A; Postel-Vinay S; Chaput N; Eggermont A; Marabelle A; Soria JC; Ferté C
    Clin Cancer Res; 2017 Apr; 23(8):1920-1928. PubMed ID: 27827313
    [No Abstract]   [Full Text] [Related]  

  • 39. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates.
    Wang C; Thudium KB; Han M; Wang XT; Huang H; Feingersh D; Garcia C; Wu Y; Kuhne M; Srinivasan M; Singh S; Wong S; Garner N; Leblanc H; Bunch RT; Blanset D; Selby MJ; Korman AJ
    Cancer Immunol Res; 2014 Sep; 2(9):846-56. PubMed ID: 24872026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors.
    Xue W; Brentville VA; Symonds P; Cook KW; Yagita H; Metheringham RL; Durrant LG
    Oncotarget; 2016 Dec; 7(50):83088-83100. PubMed ID: 27825115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 65.